Advertisement

Cellular Adoptive Immunotherapy after Bone Marrow Transplantation

  • Stanley R. Riddell
  • Philip D. Greenberg
Part of the Cancer Treatment and Research book series (CTAR, volume 76)

Abstract

Cellular adoptive immunotherapy has been broadly used to describe the transfer of effector cells of the immune system to treat malignant or infectious diseases. This approach to restoring or augmenting inadequate host immune responses is based upon several premises. Firstly, it is assumed that it will be possible to isolate effector cells from the host or a suitable donor with reactivity for the relevant tumor or pathogen. Secondly, the effector cells must be capable of being expanded in vitro to numbers sufficient to mediate therapeutic effects following adoptive transfer. Finally, it is anticipated that reinfusion of the effector cells could be accomplished without toxicity to the host and that the transferred cells would persist in vivo for a sufficient duration to eradicate the tumor or pathogen. The validity of these assumptions has been firmly established by detailed experimentation in animal models over the past two decades, but several impediments, in part based on an inadequate understanding of the biology of the effector cells potentially useful in adoptive immunotherapy, have hindered clinical applications and impacted on the success of the initial attempts at adoptive therapy for human diseases.

Keywords

Major Histocompatibility Complex Natural Killer Cell Adoptive Transfer Allogeneic Bone Marrow Transplantation Major Histocompatibility Complex Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenberg PD: Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. In Dixon F (ed): Advances in Immunology, Vol, 49. Orlando, FL: Academic Press, 1992, pp 281–355.Google Scholar
  2. 2.
    Fefer A, Einstein A, Cheever MA, Berenson J: Models for syngeneic adoptive chemo-immunoimmunotherapy of murine leukemia. Ann NY Acad Sci 276:573–583, 1976.PubMedGoogle Scholar
  3. 3.
    Mule J, Shu S, Rosenberg SA: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 185:646–652, 1985.Google Scholar
  4. 4.
    Shinomiya H, Shinomiya M, Stevenson GW, Stevenson HC: Activated killer monocytes: Preclinical model systems. Immunol Ser 48:101–126, 1989.PubMedGoogle Scholar
  5. 5.
    Ada GL, Jones PD: The immune response to influenza infection. Curr Top Microbiol Immunology 128:1–54, 1986.Google Scholar
  6. 6.
    Bukowski JF, Warner JF, Dennert G, Welsh RM: Adoptive transfer studies demonstrating the antiviral effects of NK cells in vivo. J Exp Med 161:40–52, 1985.PubMedGoogle Scholar
  7. 7.
    Doherty PC, Allan W, Eichelberger M: Roles of aβ and γδ T cell subsets in viral immunity. Annu Rev Immunol 10:123–151, 1992.PubMedGoogle Scholar
  8. 8.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492, 1985.PubMedGoogle Scholar
  9. 9.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linchan WM, Robertson CN, Lee RE, Rubin JT et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897, 1987.PubMedGoogle Scholar
  10. 10.
    Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A: Prolonged continuous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 10:960–968, 1992.PubMedGoogle Scholar
  11. 11.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ: Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine activated killer cells. Cancer Res 48:5007–5010, 1988.PubMedGoogle Scholar
  12. 12.
    Paciucci PA, Holland JF, Glidewell O, Odchimar R: Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer. J Clin Oncol 7:869–878, 1989.PubMedGoogle Scholar
  13. 13.
    Rosenberg SA, Lotze MT: Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Ann Rev Immunol 4:681–709, 1986.Google Scholar
  14. 14.
    Van Der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van Den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647, 1991.PubMedGoogle Scholar
  15. 15.
    Traversari C, Van Der Bruggen P, Luescher IF, Lurquin C, Chomez P, van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HL A-Al by cytolytic T-lymphocytes directed against tumor antigen M22-E. J Exp Med 176:1453–1457, 1992.PubMedGoogle Scholar
  16. 16.
    Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489–495, 1993.PubMedGoogle Scholar
  17. 17.
    Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating the tumor. Proc Natl Acad Sci USA 91:3515–3519, 1994.PubMedGoogle Scholar
  18. 18.
    Jung S, Schluesener HJ: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273–276, 1991.PubMedGoogle Scholar
  19. 19.
    Peace DJ, Smith JW, Chen W, You S-G, Cosand WL, Blake J, Cheever MA: Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 179:473–479, 1994.PubMedGoogle Scholar
  20. 20.
    Noguchi Y, Chen Y-T, Old LJ: A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 91:3171–3175, 1994.PubMedGoogle Scholar
  21. 21.
    Zeh HJ, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ: Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 39:79–86, 1994.Google Scholar
  22. 22.
    Chen W, Peace DJ, Rovira DK, You S-G, Cheever MA: T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 89:1468–1472, 1992.PubMedGoogle Scholar
  23. 23.
    Gambacorti-Passerini C, Grignani F, Arienti F, Pandofi PP, Pelicci PG, Parmiani G: Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 81:1369–1375, 1993.PubMedGoogle Scholar
  24. 24.
    Wilson A, George AJ, King CA, Stevenson FK: Recognition of a B cell lymphoma by anti-idiotype T cells. J Immunol 145:3937–3943, 1990.PubMedGoogle Scholar
  25. 25.
    Kwak LW, Campbell MJ, Czerwinske DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209–1215, 1992.PubMedGoogle Scholar
  26. 26.
    Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071–1076, 1994.PubMedGoogle Scholar
  27. 27.
    Ioannides GG, Fisk B, Fan D, Biddison WE, Wharton JT, O’Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 151:225–234, 1993.PubMedGoogle Scholar
  28. 28.
    Mitsuya H, Matis L, Megson M, Bunn P, Murray C, Mann D, Gallo R, Broder S: Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med 158:994–999, 1983.PubMedGoogle Scholar
  29. 29.
    Murray FJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157–168, 1992.PubMedGoogle Scholar
  30. 30.
    Thorley-Lawson DA: The suppression of in vitro Epstein-Barr virus infection occurs after infection but before transformation of the cell. J Immunol 124:745–751, 1980.PubMedGoogle Scholar
  31. 31.
    Ramsdell F, Fowlkes BJ: Clonal deletion versus clonal anergy: The role of the thymus in inducing self tolerance. Science 248:1342–1348, 1990.PubMedGoogle Scholar
  32. 32.
    Voogt PJ, Goulmy E, Veenhof WFJ, Hamilton M, Fibbe WE, van Rood JJ, Falkenburg JHF: Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med 168:2337–2347, 1988.PubMedGoogle Scholar
  33. 33.
    Falkenburg JHF, Goseling HM, van der Harst D, van Luxemburg-Heyst SAP, Kooy-Winkelaar YMC, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 174:27–33, 1991.PubMedGoogle Scholar
  34. 34.
    Oettel KR, Wesly OH, Albertini MR, Hank JA, Iliopolis O, Sosman JA, Voelkerding K, Wu S-Q, Clark SS, Sondel PM: Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1¯ cells from the same patient. Blood 83:3390–3402, 1994.PubMedGoogle Scholar
  35. 35.
    Kumar L: Leukemia: Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 12:1710–1717, 1994.PubMedGoogle Scholar
  36. 36.
    Meyers JD, Bowden RA, Counts GW: Infections after bone marrow transplantation. In Lode H, Huhn D, Melzahn M (eds): Infections in Transplant Patients. Stuttgart: Thieme, 1987, pp 17–31.Google Scholar
  37. 37.
    Trinchieri G: Biology of natural killer cells. Adv Immunol 47:187–376, 1989.PubMedGoogle Scholar
  38. 38.
    Welsh RM: Regulation of virus infections by natural killer cells. Nat Immun Cell Growth Regul 5:169–199, 1986.PubMedGoogle Scholar
  39. 39.
    Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against diseases. Science 214:24–30, 1981.PubMedGoogle Scholar
  40. 40.
    Lotzova E, Savary CA: Natural resistance to foreign hemopoietic transplants: A possible model of leukemia surveillance. Progr Clin Biol Res 132:125–135, 1983.Google Scholar
  41. 41.
    Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infection in an adolescent without natural killer cells. N Engl J Med 320:1731–1735, 1989.PubMedGoogle Scholar
  42. 42.
    Ciccone E, Pende D, Vitale M, Nanni L, Di Donato C, Bottino C, Morelli L, Viale O, Amoroso A, Moretta A, Moretta L: Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells. Eur J Immunol 24:1003–1006, 1994.PubMedGoogle Scholar
  43. 43.
    Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675–678, 1986.PubMedGoogle Scholar
  44. 44.
    Ljunggren HG, Karre K: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 162:1745–1759, 1985.PubMedGoogle Scholar
  45. 45.
    Trinchieri G: Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 180:417–421, 1994.PubMedGoogle Scholar
  46. 46.
    Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL: NKB1: A natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 180:537–543, 1994.PubMedGoogle Scholar
  47. 47.
    Moretta A, Vitale M, Sivori S, Bottino C, Morelli L, Augugliaro R, Barbaresi M, Pende D, Ciccone E, Lopez-Botet M, Moretta L: Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B molecules. J Exp Med 180:545–555, 1994.PubMedGoogle Scholar
  48. 48.
    Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA 86:2361–2364, 1989.PubMedGoogle Scholar
  49. 49.
    Shimizu Y, DeMars R: Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol 19:447–451, 1989.PubMedGoogle Scholar
  50. 50.
    Vegh Z, Wang P, Vanky F, Klein E: Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res 53:2416–2420, 1983.Google Scholar
  51. 51.
    Anderssen ML, Stam NJ, Klein G, Ploegh H, Masucci MG: Aberrant expression of HLA class I antigens in Burkitt lymphoma cells. Int J Cancer 47:544–550, 1991.Google Scholar
  52. 52.
    Duncombe AS, Grundy JE, Oblakowski P, Prentice HG, Gottlieb DJ, Roy DM, Reittie JE, Bello-Fernandez C, Hoffbrand AV, Brenner MK: Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: The importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood 79:3059–3066, 1992.PubMedGoogle Scholar
  53. 53.
    Barnes PD, Grundy JE: Down regulation of the class I HLA heterodimer and β-2 microglobulin on the surface of cells infected with cytomegalovirus. J Gen Virol 73:2395–2403, 1992.PubMedGoogle Scholar
  54. 54.
    Warren AP, Ducroq DH, Lehner PJ, Borysiewicz LK: Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol 68:2822–2829, 1994.PubMedGoogle Scholar
  55. 55.
    Beersma MFC, Bijlmakers JJE, Ploegh HL: Human cytomegalo virus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 151:4455–4464, 1993.PubMedGoogle Scholar
  56. 56.
    York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77:525–535, 1994.PubMedGoogle Scholar
  57. 57.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous peripheral blood lymphocytes. J Exp Med 155:1823–1840, 1982.PubMedGoogle Scholar
  58. 58.
    Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis of LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Institute 75:67–75, 1985.Google Scholar
  59. 59.
    Mule JJ, Smith CA, Rosenberg SA: Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity against fresh tumor cells. J Exp Med 166:792–797, 1987.PubMedGoogle Scholar
  60. 60.
    Grimm EA, Wilson DJ: The human lymphokine activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol 94:568–578, 1984.Google Scholar
  61. 61.
    Sondel PM, Hank JA, Kohler PC, Chen BC, Minkoff DZ, Molenda JA: Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol 137:502–511, 1986.PubMedGoogle Scholar
  62. 62.
    Malkovsdy M, Loveland B, North M, Asherson GL, Gao L, Ward P, Fiers W: Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes Nature 325:262–265, 1987.Google Scholar
  63. 63.
    Damle NK, Doyle L, Bradley E: Interleukin-2 activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137:2814–2822, 1987.Google Scholar
  64. 64.
    Lotzova E, Ades E: Natural killer cells: Definition, heterogeneity, lytic mechanism, functions and clinical application. Natl Immunol Cell Growth Regul 8:1–9, 1989.Google Scholar
  65. 65.
    Lotzova E, Savary CA, Herberman RB: Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors Leuk Res 11: 1059–1066, 1987.Google Scholar
  66. 66.
    Oshimi K, Oshimi Y, Akutsu M, et al.: Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938–948, 1986.PubMedGoogle Scholar
  67. 67.
    Lotzova E, Savary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138:2718–2727, 1987.PubMedGoogle Scholar
  68. 68.
    Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, Ip S, Rosen F, Krangel MS: Identification of a putative second T cell receptor. Nature 322:145–149, 1986.PubMedGoogle Scholar
  69. 69.
    Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ: Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocytes clones. J Exp Med 163:903–921, 1986.PubMedGoogle Scholar
  70. 70.
    Mosmann TR, Coffman RL: Heterogeneity of cytokine secretion patterns and functions of helper T cells. In Dixon F (ed): Advances in Immunology, Vol. 46. Orlando, FL: Academic Press, 1989, 111–147.Google Scholar
  71. 71.
    Sverdersky LP, Shepard HM, Spencer SA, Shalaby MR, Palladino MA: Augmentation of human natural cell-mediated cytotoxicity by recombinant interleukin 2. J Immunol 133:714–718, 1984.Google Scholar
  72. 72.
    Kern DE, Grabstein KA, Schreiber KD, Greenberg PD: Identification of an unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity. J Immunol 143:4308–4316, 1989.PubMedGoogle Scholar
  73. 73.
    Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403–450, 1993.PubMedGoogle Scholar
  74. 74.
    Long EO: Antigen processing for presentation to CD4+ T cells. New Biol 4:274–282, 1992.PubMedGoogle Scholar
  75. 75.
    Mosmann TR, Coffman RL: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 5:305–324, 1989.Google Scholar
  76. 76.
    Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357, 1986.PubMedGoogle Scholar
  77. 77.
    Romagnani S: Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98:279–285, 1992.PubMedGoogle Scholar
  78. 78.
    Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Thl murine helper T lymphocyte clones. J Immunol 140:4245–4254, 1988.PubMedGoogle Scholar
  79. 79.
    Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, Murphy KM: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547–549, 1993.PubMedGoogle Scholar
  80. 80.
    Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968–980, 1982.PubMedGoogle Scholar
  81. 81.
    Yewdell JW, Bennink JR: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. In Dixon F (ed): Advances in Immunology, Vol. 52. Orlando, FL: Academic Press, 1992, pp 1–123.Google Scholar
  82. 82.
    Brown MG, Driscoll J, Monaco JJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353:355–357, 1991.PubMedGoogle Scholar
  83. 83.
    Spies T, Bresnhan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348:744–777, 1990.PubMedGoogle Scholar
  84. 84.
    Spies T, DeMars R: Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature 351:323–324, 1991.PubMedGoogle Scholar
  85. 85.
    Ortmann B, Androlewicz MJ, Cresswell P: MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding. Nature 368:864–867, 1994.PubMedGoogle Scholar
  86. 86.
    van Bleek GM, Nathenson SG: Presentation of antigenic peptides by MHC class I molecules. Trends Cell Biol 2:202–207, 1992.PubMedGoogle Scholar
  87. 87.
    Doherty PC: Cell mediated cytotoxicity. Cell 75:607–612, 1993.PubMedGoogle Scholar
  88. 88.
    Fong FA, Mosmann TR: Alloreactive murine T cell clones secrete the TH1 pattern of cytokines. J Immunol 144:1744–1752, 1990.PubMedGoogle Scholar
  89. 89.
    Gessner A, Moskophidis D, Lehman-Grube F: Enumeration of single IFN y producing cells in mice during viral infection and bacterial infection. J Immunol 142:1293–1298, 1989.PubMedGoogle Scholar
  90. 90.
    Koszinowski UH, Reddehase MJ, Jonjic S: The role of CD4 and CD8 T cells in viral infections. Curr Opin Immunol 3:471–475, 1991.PubMedGoogle Scholar
  91. 91.
    Rosenberg SA, Mule J, Spiess P, Reicher CM, Schwartz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169–1188, 1985.PubMedGoogle Scholar
  92. 92.
    Lafreniere R, Rosenberg SA: Successful immunotherapy of experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukin-2. Cancer Res 45:3735–3741, 1985.PubMedGoogle Scholar
  93. 93.
    Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159:495–507, 1984.PubMedGoogle Scholar
  94. 94.
    Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA: Eradication of disseminated murine leukemia by treatment with high dose interleukin-2. J Immunol 137:3675–3680, 1986.PubMedGoogle Scholar
  95. 95.
    Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321, 1986.PubMedGoogle Scholar
  96. 96.
    Fass L, Fefer A: Studies of adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res 32:997–1001, 1972.PubMedGoogle Scholar
  97. 97.
    Greenberg PD, Cheever MA, Fefer A: Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res 40:4428–4432, 1980.PubMedGoogle Scholar
  98. 98.
    Greenberg PD, Cheever MA: Treatment of disseminated leukemia with cyclophosphamide and immune cells: Tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol 133:3401–3407, 1984.PubMedGoogle Scholar
  99. 99.
    Greenberg PD: Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: Cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol 136:1917–1922, 1986.PubMedGoogle Scholar
  100. 100.
    Klarnet JP, Matis LA, Kern DE, Mizuno MT, Peace DJ, Thompson JA, Greenberg PD, Cheever MA: Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia and provide specific immunologic memory. J Immunol 138:4012–4017, 1987.PubMedGoogle Scholar
  101. 101.
    Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM: In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J Exp Med 179: 1215–1224, 1994.PubMedGoogle Scholar
  102. 102.
    Klarnet JP, Kern DE, Okuno K, Holt C, Lilly F, Greenberg PD: FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-enkoded antigens. J Exp Med 169:457–467, 1989.PubMedGoogle Scholar
  103. 103.
    Greenberg PD, Kern DE, Cheever MA: Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-l+2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161:1122–1134, 1985.PubMedGoogle Scholar
  104. 104.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T: The role of tumor-specific Lyt-l+2-T cells in eradicating tumor cells in vivo. I. Lyt-l+2-T cells do not necessarily require recruitment of host’s cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 133:1671–1676, 1984.PubMedGoogle Scholar
  105. 105.
    Mills CD, North RJ: Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med 157:1448–1460, 1983.PubMedGoogle Scholar
  106. 106.
    Schild HJ, Kyewski B, von Hoegen P, Schirrmacher V: CD4+ helper T cells are required for resistance to a highly metastatic tumor. Eur J Immunol 17:1863–1866, 1987.PubMedGoogle Scholar
  107. 107.
    Yoshioka T, Fukuzawa M, Takai Y, Wakamiya N, Ueda S, Kato S, Fujiwara H: The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-l+2-T cells is responsible for augmented tumor immunity in vivo. Cancer Immunol Immunother 21:193–198, 1986.Google Scholar
  108. 108.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE: Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J Immunol 141:1047–1053, 1988.PubMedGoogle Scholar
  109. 109.
    Barker E, Mokyr MB: Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells. Cancer Res 48:4834–4842, 1988.PubMedGoogle Scholar
  110. 110.
    Awwad M, North RJ: Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+T cell-mediated immunity. J Exp Med 168:2193–2206, 1988.PubMedGoogle Scholar
  111. 111.
    June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15:321–331, 1994.PubMedGoogle Scholar
  112. 112.
    Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada G, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543, 1993.PubMedGoogle Scholar
  113. 113.
    Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403, 1990.PubMedGoogle Scholar
  114. 114.
    Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete nterleukin-4. Science 254:713–716, 1991.PubMedGoogle Scholar
  115. 115.
    Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368–370, 1993.PubMedGoogle Scholar
  116. 116.
    Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093–1102, 1992.PubMedGoogle Scholar
  117. 117.
    Tepper RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene Ther 5:153–164, 1994.Google Scholar
  118. 118.
    Campbell MJ, Esserman L, Levy R: Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 141:3227–3236, 1988.PubMedGoogle Scholar
  119. 119.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R: Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: Active immunization with tumor-derived idiotypic immunoglobulin. Blood 76:2411–2427, 1990.PubMedGoogle Scholar
  120. 120.
    Cheever MA, Greenberg PD, Irle C, Thompson JA, Urdal DL, Mochizuki DY, Henney CS, Gillis S: Interleukin-2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol 132:2259–2265, 1984.PubMedGoogle Scholar
  121. 121.
    Cheever MA, Greenberg PD, Fefer A: Specific adoptive immunotherapy of estabilished leukemia with syngeneic lymphocytes nonspecifically expanded by culture with interleukin 2. J Immunol 126:1318–1322, 1981.PubMedGoogle Scholar
  122. 122.
    Shanley JD, Jordan MC, Cook ML, Stevens JG: Pathogenesis of reactivated latent murine cytomegalovirus infection. Am J Pathol 95:67–77, 1979.PubMedGoogle Scholar
  123. 123.
    Mutter W, Reddehase MJ, Busch FW, Buhring HJ, Koszinowski UH: Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host. J Exp Med 167:1645–1658, 1988.PubMedGoogle Scholar
  124. 124.
    Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A, Koszinowski UH: Interstitial murine CMV pneumonia after irradiation: Characterization of the cells that limit viral replication. J Virol 55:264–273, 1985.PubMedGoogle Scholar
  125. 125.
    Reddehase MJ, Mutter W, Munch K, Buhring H-J, Koszinowski UH: CD8-positive T lymphocytes specific for murine cytomegalovirus immediate early antigens mediate protective immunity. J Virol 61:3102–3108, 1987.PubMedGoogle Scholar
  126. 126.
    Reddehase MJ, Koszinowski UH: Significance of herpes virus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312:369–371, 1984.PubMedGoogle Scholar
  127. 127.
    Lukacher AE, Braciale VL, Braciale TF: In vivo effector function of influenza virus-specific T lymphocyte clones is highly specific. J Exp Med 160:814–823, 1984.PubMedGoogle Scholar
  128. 128.
    Baenziger J, Hengartner H, Zinkernagel R, Cole G: Induction or prevention of immuno-pathologic disease by cloned cytotoxic T cell lines specific for lymphocytic choriomeningitis virus. Eur J Immunol 16:387–395, 1986.PubMedGoogle Scholar
  129. 129.
    Cannon M, Openshaw P, Askonsas B: Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncyticial virus J Exp Med 168:1163–1168, 1988.Google Scholar
  130. 130.
    Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632, 1993.PubMedGoogle Scholar
  131. 131.
    Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A: Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159–163, 1993.PubMedGoogle Scholar
  132. 132.
    Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964–971, 1994.PubMedGoogle Scholar
  133. 133.
    Topalian S, Solomon D, Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanoma. J Immunol 142:3714–3725, 1989.PubMedGoogle Scholar
  134. 134.
    Topalian S, Muul LM, Solomon D, Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127–141, 1987.PubMedGoogle Scholar
  135. 135.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, et al.: Use of tumor-infilitrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680, 1988.PubMedGoogle Scholar
  136. 136.
    Aebersold P, Hyatt C, Johnson S, et al.: Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: Association with clinical response. J Natl Cancer Inst 83: 932–937, 1991.PubMedGoogle Scholar
  137. 137.
    Rosenberg SA, Aebersold P, Cornetta K, et al.: Gene transfer into humans — immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578, 1990.PubMedGoogle Scholar
  138. 138.
    Barnes DWH, Loutit JF: Treatment of murine leukaemia with X-rays and homologous bone marrow II. Br J Haematol 3:241–252, 1957.PubMedGoogle Scholar
  139. 139.
    Weiden PL, Flournoy N, Thomas ED, et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068–1073, 1979.PubMedGoogle Scholar
  140. 140.
    Weiden PL, Sullivan KM, Flournoy N, et al.: Antileukemic effect of chronic graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529–1533, 1981.PubMedGoogle Scholar
  141. 141.
    Apperly JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle D, et al.: Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect. Br J Haematol 69:239–245, 1988.Google Scholar
  142. 142.
    Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, et al.: Graft versus leukemia reactions after bone marrow transpantation. Blood 75:555–562, 1990.PubMedGoogle Scholar
  143. 143.
    Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–568, 1991.PubMedGoogle Scholar
  144. 144.
    Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 8:2273–2277, 1993.Google Scholar
  145. 145.
    Fefer A, Sullivan KM, Weiden P: Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. In Truitt R, Gale RP, Bortin MM (eds): Cellular Immunotherapy of Cancer. New York: Alan R. Liss, 1987; pp 401–408.Google Scholar
  146. 146.
    Collins RH, Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transpant 10:391–395, 1992.Google Scholar
  147. 147.
    Higano CS, Brixley M, Bryant EH, et al.: Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. Transplantation 50:175–177, 1990.PubMedGoogle Scholar
  148. 148.
    Sullivan KM, Storb R, Buckner CD, et al.: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320: 828–834, 1989.PubMedGoogle Scholar
  149. 149.
    Sullivan KM, Deeg H, Sanders J, et al.: Hyperacute graft-versus-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 67:1172–1175, 1986.PubMedGoogle Scholar
  150. 150.
    Goldman JM, Gale RP, Horowitz MM, et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806–814, 1988.PubMedGoogle Scholar
  151. 151.
    Apperly JF, Jones L, Hale G, et al.: Bone marrow transplantation for patients with chronic myeloid leukemia: T cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemia relapse. Bone Marrow Transplant 1:53–66, 1986.Google Scholar
  152. 152.
    Kolb HJ, Mittermuller J, Clemm Ch, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465, 1990.PubMedGoogle Scholar
  153. 153.
    Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310–2318, 1993.PubMedGoogle Scholar
  154. 154.
    Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 12:125–129, 1993.PubMedGoogle Scholar
  155. 155.
    Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsee chronic myeloid leukemia. N Engl J Med 330:100–106, 1994.PubMedGoogle Scholar
  156. 156.
    Cullis JO, Jiang YZ, Schwarer AP, et al.: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79:1379–1381, 1992.PubMedGoogle Scholar
  157. 157.
    Bar BMAM, Schattenberg A, Mensink EJBM, et al.: Donor leukocyte infusions for chronic myeloid leukemia after allogeneic bone marrow transplantation. J Clin Oncol 11:513–519, 1993.PubMedGoogle Scholar
  158. 158.
    Kolb HJ, de Witte T, Mittermuller J, et al.: Graft-versus-leukemia effect of donor buffy coat transfusion on recurrent leukemia after marrow transplantation. Blood 82(Suppl l):840A, 1993.Google Scholar
  159. 159.
    van Lochern E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181–183, 1992.Google Scholar
  160. 160.
    Hoffmann T, Theobald M, Bunjes D, Weiss M, Heimpel H, Heit W: Frequency of bone marrow T cells responding to HLA-identical non-leukemia and leukemic stimulator cells. Bone Marrow Transplant 12:1–8, 1993.PubMedGoogle Scholar
  161. 161.
    Carroll WL, Thielemens K, Dilley J, Levy R: Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61–72, 1986.PubMedGoogle Scholar
  162. 162.
    Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK: Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83:3279–3288, 1994.PubMedGoogle Scholar
  163. 163.
    Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755–758, 1993.PubMedGoogle Scholar
  164. 164.
    Cooney EL, Corey L. Hu S-L, et al.: Enhanced immunity to HIV envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp 160 protein. Proc Natl Acad Sci USA 90:1882–1886, 1993.PubMedGoogle Scholar
  165. 165.
    Laube LS, Burrascano M, Dejesus CE, et al.: Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB env/rev proteins. Hum Gene Therapy 5:853–862, 1994.Google Scholar
  166. 166.
    Ulmer JB, Donnelly JJ, Parker SE, et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749, 1993.PubMedGoogle Scholar
  167. 167.
    Kwak LW, Taub DD, Duffey PL, Bensinger WI, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunized allogeneic bone marrow donor. Blood 82 (Suppl 1):787A, 1993.Google Scholar
  168. 168.
    Witherspoon RP, Mathews D, Storb R, et al.: Recovery of cellular immunity after human marrow grafting: Influence of time post-grafting and acute graft-versus-host disease. Transplantation 37:145–150, 1984.PubMedGoogle Scholar
  169. 169.
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241, 1992.PubMedGoogle Scholar
  170. 170.
    Sarai R, Burns WH, Laskin OL, Santos GW, Lietman PS: Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 305:63–67, 1981.Google Scholar
  171. 171.
    Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324:1005–1011, 1991.PubMedGoogle Scholar
  172. 172.
    Goodrich JM, Mori M, Gleaves CA, et al.: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601–1607, 1991.PubMedGoogle Scholar
  173. 173.
    Goodrich JM, Bowden RA, Fisher L, et al.: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178, 1993.PubMedGoogle Scholar
  174. 174.
    Erice A, Chow SW, Biron K, et al.: Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised humans. N Engl J Med 320:289–292, 1989.PubMedGoogle Scholar
  175. 175.
    Meyers JD, Flournoy N, Thomas ED: Cytomegalovirus infection and specific cell mediated immunity after marrow transplant. J Infect Dis 142:816–824, 1980.PubMedGoogle Scholar
  176. 176.
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR: Recovery of MHC-restricted CMV-specific T cell responses after allogeneic marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971–1979, 1994.PubMedGoogle Scholar
  177. 177.
    Quinnan GV, Kirmani N, Esber E, Sarai R, Manischewitz J, Rogers JL, Rook AH, Santos GW, Burns WH: HLA-restricted cytotoxic T lymphocytes and non thymic cytotoxic lymphocyte responses to cytomegalovirus infections of bone marrow transplant recipients. J Immunol 126:2031–2041, 1981.Google Scholar
  178. 178.
    Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T lymphocyte response to cytomegalovirus following allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380, 1991.PubMedGoogle Scholar
  179. 179.
    Borysiewicz LK, Graham S, Hickling JK, Sissons JGP: Precursor frequency and stage specificity of human cytomegalovirus-specific cytotoxic T cells. Eur J Immunol 18: 269–275, 1988.PubMedGoogle Scholar
  180. 180.
    Riddell SR, Greenberg PD: The use of anti CD3 and anti CD28 monoclonal antibodies to clone and expand antigen-specific T cells. J Immunol Methods 128:189–197, 1990.PubMedGoogle Scholar
  181. 181.
    Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD: Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795–2804, 1991.PubMedGoogle Scholar
  182. 182.
    McLaughin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia J, Greenberg PD, Riddell SR: Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103–110, 1994.Google Scholar
  183. 183.
    Gilbert MJ, Riddell SR, Li CR, Greenberg PD: Selective interference with class I presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 67:3461–3469, 1993.PubMedGoogle Scholar
  184. 184.
    de Campos-Lima PO, Gavioli R, Zhang Q-J, Wallace L, Dolcetti R, Rowe M, Rickinson A, Masucci M: HLA-11 epitope loss isolates of Epstein-Barr virus from a highly A11 + population. Science 260:98–100, 1993.PubMedGoogle Scholar
  185. 185.
    Phillips R, Rowland-Jones S, Nixon D, et al.: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453–459, 1991.PubMedGoogle Scholar
  186. 186.
    Gratama JW: Epstein Barr virus infections in bone marrow transplantation recipients. In Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge, MA: Blackwell Scientific, 1994, pp 429–442.Google Scholar
  187. 187.
    Shapiro RS, McClain K, Frizzera G, et al.: Epstein-Barr virus associateci B cell lymphoproliferative disorders after bone marrow transplantation. Blood 71:1234–1243, 1988.PubMedGoogle Scholar
  188. 188.
    Zutter MM, Martin PJ, Sale GE, et al.: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520–529, 1988.PubMedGoogle Scholar
  189. 189.
    Middleton T, Gahn TA, Martin JM, Sugden B: Immortalizing genes of Epstein-Barr virus. Adv Virus Rese 40:19–55, 1991.Google Scholar
  190. 190.
    Papadopoulos E, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O’Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185–1191, 1994.PubMedGoogle Scholar
  191. 191.
    Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:1329–1336, 1993.Google Scholar
  192. 192.
    Riddell SR, Gilbert MJ, Greenberg PD: CD8+ cytotoxic T cell therapy of cytomegalovirus and human immunodeficiency virus infection. Curr Opin Immunol 5:484–491, 1993.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Stanley R. Riddell
  • Philip D. Greenberg

There are no affiliations available

Personalised recommendations